WallStSmart
SNDX

Syndax Pharmaceuticals Inc

NASDAQ: SNDX · HEALTHCARE · BIOTECHNOLOGY

$20.65
+2.74% today

Updated 2026-05-06

Market cap
$1.69B
P/E ratio
P/S ratio
7.79x
EPS (TTM)
$-2.79
Dividend yield
52W range
$9 – $26
Volume
1.6M

Syndax Pharmaceuticals Inc (SNDX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+2.8%
Last 4 quarters
Revenue YoY growth
+791.7%
Most recent quarter
EPS YoY growth
+29.1%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+15.8%
Last 3 reports
Positive reaction rate
100%
3 of 3 quarters
Largest single-day move
+26.0%
2025-08-04
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-09$-0.78-33.2%$22.07$24.16+9.5%
2025-11-03$-0.70+4.1%$13.70$15.35+12.0%
2025-08-04$-0.83+17.8%$9.98$12.57+26.0%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.59$-0.78-33.2%$68.48M+791.7%
2025-09-30$-0.73$-0.70+4.1%$45.87M+267.0%
2025-06-30$-1.01$-0.83+17.8%$37.96M+984.5%
2025-03-31$-1.27$-0.98+22.7%$20.04M
2024-12-31$-0.23$-1.10-380.6%$7.68M+1332.8%
2024-09-30$-1.11$-0.98+11.7%$12.50M
2024-06-30$-0.91$-0.80+12.1%$3.50M
2024-03-31$-0.98$-0.85+13.3%
2023-12-31$-0.99$-1.00-1.0%$536000.00
2023-09-30$-0.80$-0.73+8.8%
2023-06-30$-0.73$-0.64+12.3%

Frequently asked questions

Has Syndax Pharmaceuticals Inc beaten earnings estimates?
Syndax Pharmaceuticals Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +2.8% over the last 4 quarters.
How does SNDX stock react to earnings?
SNDX stock has moved an average of +15.8% in the trading day following earnings over its last 3 reports, with positive reactions in 100% of those quarters.
What is Syndax Pharmaceuticals Inc's revenue growth rate?
Syndax Pharmaceuticals Inc reported year-over-year revenue growth of +791.7% in its most recent quarter, with EPS growing +29.1% year-over-year.